Successful Postpartum CAR T-cell Salvage Therapy for Primary Mediastinal Large B-cell Lymphoma with Residual Disease after R-CHOP During Pregnancy
Abstract
Primary mediastinal large B-cell lymphoma (PMBCL) during pregnancy is rare and presents therapeutic challenges due to fetal safety concerns. We report the case of a 29-year-old woman diagnosed with PMBCL at 19 weeks of gestation who wished to continue her pregnancy despite her diagnosis. She received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy with multidisciplinary management and delivered a healthy infant at term. Although the tumor partially responded, residual disease persisted after eight cycles of treatment. She subsequently underwent chimeric antigen receptor T-cell therapy and achieved a complete response. This case highlights the importance of individualized treatment decisions and multidisciplinary collaboration in managing PMBCL during pregnancy.
Related
- Diffuse Nephromegaly With Dialysis‐Dependent Acute Kidney Injury as the Initial Presentation of Primary Mediastinal Large B‐Cell Lymphoma
- First Presentation With Impending Cardiac Tamponade Leading to a New Diagnosis of Mediastinal Lymphoma: A Shared Learning Case on the Atypical Presentation of Pericardial Effusion and Cardiac Tamponade.
- Telemedicine-Guided Pericardiocentesis for Cardiac Tamponade in Primary Mediastinal Large B-cell Lymphoma.
- Clinical-MRI-IVIM combined model for differentiating thymic epithelial tumors from anterior mediastinal lymphoma in large masses
- Successful Treatment with Epcoritamab for Refractory Diffuse Large B-cell Lymphoma in a Dialysis-dependent Patient
BibTeX
@article{uemura2026successful,
title = {{Successful Postpartum CAR T-cell Salvage Therapy for Primary Mediastinal Large B-cell Lymphoma with Residual Disease after R-CHOP During Pregnancy}},
author = {Misaki Uemura and Atsushi Marumo and Yuta Kaito and Toshikazu Itabashi and Ikuno Kawabata and Yu Yagi and Tatsu Shimoyama and Yasunobu Nagata and Satoshi Wakita and Hiroki Yamaguchi},
journal = {Internal Medicine},
year = {2026},
month = jul,
doi = {10.2169/internalmedicine.7549-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7549-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Successful Postpartum CAR T-cell Salvage Therapy for Primary Mediastinal Large B-cell Lymphoma with Residual Disease after R-CHOP During Pregnancy
AU - Misaki Uemura
AU - Atsushi Marumo
AU - Yuta Kaito
AU - Toshikazu Itabashi
AU - Ikuno Kawabata
AU - Yu Yagi
AU - Tatsu Shimoyama
AU - Yasunobu Nagata
AU - Satoshi Wakita
AU - Hiroki Yamaguchi
PY - 2026
DA - 2026/07/04
JO - Internal Medicine
DO - 10.2169/internalmedicine.7549-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7549-26/_article
AB - Primary mediastinal large B-cell lymphoma (PMBCL) during pregnancy is rare and presents therapeutic challenges due to fetal safety concerns. We report the case of a 29-year-old woman diagnosed with PMBCL at 19 weeks of gestation who wished to continue her pregnancy despite her diagnosis. She received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy with multidisciplinary management and delivered a healthy infant at term. Although the tumor partially responded, residual disease persisted after eight cycles of treatment. She subsequently underwent chimeric antigen receptor T-cell therapy and achieved a complete response. This case highlights the importance of individualized treatment decisions and multidisciplinary collaboration in managing PMBCL during pregnancy.
SN - 1349-7235
SN - 0918-2918
ER -